Santhera Publishes Timeline of the Reverse Share Split NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER...
Santhera’s Aktionäre stimmen an heutiger Generalversammlung allen Anträgen des Verwaltungsrats zu Pratteln, Schweiz, 27. Juni 2023 –...
Santhera vergibt exklusive Nordamerika-Lizenz für Vamorolone an Catalyst Pharmaceuticals in einer Transaktion im Wert von bis zu USD 231...
Santhera veröffentlicht Einladung zur ordentlichen Generalversammlung NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR...
Santhera Publishes Annual Report 2022 Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, May 31, 2023 – Santhera...
Santhera Announces Preliminary Unaudited 2022 Annual Results Ahead of Full Report Publication by End of May and Provides Corporate Update Ad...
Vamorolone NDA mid-cycle review meeting by FDA completed Pratteln, Switzerland, and Rockville, MD, USA, April 25, 2023 – Santhera...
Santhera reicht bei der britischen Arzneimittelbehörde MHRA einen Zulassungsantrag für Vamorolone zur Behandlung von Duchenne-Muskeldystrophie...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads